Johnson & Johnson reported adjusted earnings of $2.59 per share in the third quarter, beating Wall Street expectations of $2.54. Quarterly revenue reached $25.4 billion, driven by pharmaceutical sales up 7.7% to $16.76 billion, including 68% growth for Tremfya to $2.4 billion. The Middle East conflict weighed on the medical-devices division, with international sales remaining flat. J&J raised its full-year revenue forecast to approximately $101.2 billion and its adjusted earnings target to $11.10 per share.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
